[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polycystic-kidney-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polycystic-kidney-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100582758","effects-of-exogenous-ketosis-on-proteinuria-and-renal-function-100582758",false,"NCT06867471","Effects of Exogenous Ketosis on Proteinuria and Renal Function","Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Patients with Polycystic Kidney Disease","KETO-CKD","Inclusion Criteria\n\nStudy A (patients with CKD):\n\n* ACR \\> 200 mg\u002Fg \\\u003C3000 mg\u002Fg\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers and SGLT-2 inhibitors for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nStudy B (patients with PKD):\n\n* Prior diagnose with PKD\n* eGFR \\>30 ml\u002Fmin\u002F1,73m2\n* Treatment with Renin-Angiotension System (RAS) blockers for a minimum of 4 weeks prior to inclusion\n* Safe contraception if women in childbearing age\n\nExclusion Criteria (Study A+B)\n\n* Diabetes Mellitus type 1\n* Heart Failure\n* Liver Disease\n* Kidney transplant\n* Malignant diseases (except skin cancer)\n* Recent acute myocardial infarction (AMI), apoplexia\u002Ftransient ischemic attack (TIA) (within 3 months of inclusion)\n* Pregnancy or breast feeding\n* Alcohol or drug abuse\n* Periodic fasting within four weeks of inclusion\n* Routinely intake of ketogenic diet within four weeks of inclusion\n* Treatment with nitrate","ALL","18 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24],"NA","A randomized, placebo-controlled, double-blinded crossover study will be conducted. Fourteen patients with polycystic kidney disease (PKD) and 29 patients with proteinuric kidney disease will receive ketone bodies (Ketone-IQ) and placebo in a randomized order. Each treatment period is four weeks. There will be a wash-out period of two weeks in between treatment periods. Effect variables will be measured in the last day of each treatment period.",[27,28,29,30],"Renal Insufficiency, Chronic","Polycystic Kidney Diseases","Proteinuria","Ketosis",[32,33,34,30,29,35],"Kidney physiology","Glomerular Filtration Rate","Chronic Kidney disease","Natriuresis","RECRUITING","2025-03-06",{"date":39,"type":40},"2025-03-10","ACTUAL",{"date":42,"type":40},"2024-09-11",{"date":44,"type":21},"2025-12",{"name":46,"class":47},"Gødstrup Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100365500","adpkd-patient-registry-100365500","NCT04039061","ADPKD Patient Registry","Autosomal Dominant Polycystic Kidney Disease Patient Registry","ADPKD","Inclusion Criteria:\n\n* Diagnosis or suspected diagnosis with autosomal dominant polycystic kidney disease (ADPKD)\n\nExclusion Criteria:\n\n* caretakers, family members or friends of individuals with ADPKD",{"count":58,"type":21},3000,"10 Years","OBSERVATIONAL","The purpose of the ADPKD Registry is to create an online patient network that includes at least 5,000 people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who contribute data on their health and other topics. The ADPKD Patient Registry aims to support important scientific discoveries and support patient needs in the following ways:\n\n* Connect ADPKD patients with opportunities to join clinical studies.\n* Collect data for the research community to better describe the ADPKD disease experience and improve patient care.\n* Engage with patients by measuring quality of life outcomes.",[28],"2023-11-15",{"date":65,"type":40},"2023-11-18",{"date":67,"type":40},"2019-09-04",{"date":69,"type":21},"2029-09-04",{"name":71,"class":47},"PKD Foundation"]